Bristol Myers Squibb stock edges higher as new multiple myeloma approval and collaboration milestone support outlook

Bristol Myers Squibb stock (ISIN US0897961004) is trading in the mid-$60 range, with a closing price of $64.66 on August 13, 2026, as the company benefits from a new U.S. approval in multiple myeloma and a fresh collaboration milestone payment in cardiology.

Fresh FDA approval in multiple myeloma

On August 13, 2026, Bristol Myers Squibb announced that the U.S. Food and Drug Administration granted accelerated approval to the company’s ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj plus dexamethasone (ZDd) for adult patients with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The approval announcement dated August 13, 2026, highlights that this regimen targets patients who have already been treated with key standard agents.

This accelerated approval strengthens Bristol Myers Squibb’s hematology and oncology portfolio by adding a new option aimed at patients whose disease has progressed after initial therapies, a group with significant unmet need. The multiple myeloma market remains competitive, but adding an iberdomide-based regimen can help Bristol Myers Squibb defend and expand its presence in this indication.

For investors, the timing of the FDA decision in mid-August 2026 provides a clear near-term catalyst, as commercial rollout and uptake will be watched closely in subsequent quarters. The company’s ability to convert regulatory momentum into revenue growth is likely to feature prominently in upcoming earnings discussions.

Collaboration milestone underscores cardiology pipeline

Beyond oncology, Bristol Myers Squibb is also advancing its cardiovascular ambitions through external partnerships. In August 2026, Atrium Therapeutics reported that it achieved a second milestone under its global cardiovascular collaboration with Bristol Myers Squibb, triggering a $15 million payment that will be recognized in Atrium’s third quarter financial statements. The Atrium Therapeutics second quarter 2026 update notes that the August milestone payment of $15 million reflects progress under the collaboration.

Atrium described this August milestone as being tied to the delivery of a lead compound targeting an undisclosed cardiology indication, which underscores Bristol Myers Squibb’s strategy of using partnered RNA therapeutics to complement its in-house cardiovascular pipeline. A regulatory filing for Atrium indicates that the August 2026 milestone under the BMS collaboration is valued at $15 million.

From a financial perspective, the $15 million milestone itself is modest relative to Bristol Myers Squibb’s overall revenue base, but the event sends a broader signal regarding the company’s commitment to cardiology innovation. As partnered programs advance through milestones, they can ultimately feed a pipeline of future registrational trials and potential launches, supporting long-term growth beyond the current oncology-heavy portfolio.

For comparison, Atrium’s collaboration revenue for the second quarter of 2026 totaled $3.0 million, largely related to research and development services under its agreement with Bristol Myers Squibb, while the newly earned $15 million milestone will be reflected in the third quarter. The same Atrium update reports collaboration revenue of $3.0 million for the second quarter of 2026 and highlights that the second BMS collaboration milestone will be accounted for in the third quarter. This illustrates how Bristol Myers Squibb’s external spending is translating into pipeline advancement for both partners.

Analyst targets and valuation context

On the market side, Bristol Myers Squibb shares are quoted at $64.66, with TradingKey data showing a closing price of $64.655 and a gain of 1.50 percent on August 13, 2026, compared with the prior session. A real-time snapshot lists the latest Bristol Myers Squibb price at $64.66 with a 1.50 percent daily increase as of the August 13, 2026 close.

Consensus expectations suggest limited upside from current levels. A forecast overview indicates that the average analyst price target implies a projected upside of 1.76 percent from a reference price of $64.92, putting the average target only slightly above where the stock currently trades. One forecast page notes that the average price target represents an upside of 1.76 percent from a current price of $64.92.

The narrow gap between the $64.92 reference price and the average target underscores that, at least on consensus numbers, Bristol Myers Squibb stock is viewed as fairly valued rather than deeply discounted. With the shares at $64.66, the implied upside to the average target is less than 2 percent, indicating that future performance will need to come from earnings delivery and pipeline execution rather than simple multiple expansion.

Institutional ownership data also shows a broad base of professional investors. As of the first quarter of 2026, TradingKey reports that 4,176 institutions hold Bristol Myers Squibb shares, collectively accounting for 84.35 percent of total shares. An ownership overview lists 4,176 institutional holders in 2026Q1, with their stakes representing 84.35 percent of Bristol Myers Squibb shares. A high institutional participation rate can support liquidity and, over time, can lead to active engagement around capital allocation and strategic decisions.

Market performance and historical benchmarks

Looking at recent trading history, data from early August 2026 show Bristol Myers Squibb closing at $65.89 on August 4, 2026, after trading between an intraday low of $63.87 and a high of $66.31, with volume of 23,292,832 shares. A historical quote table for August 4, 2026 lists an open of $64.89, a high of $66.31, a low of $63.87 and a close of $65.89 on volume of 23,292,832 shares.

Comparing the August 13, 2026 closing level of $64.66 to the August 4, 2026 close of $65.89 highlights a modest pullback of $1.23, which equates to a decline of roughly 1.9 percent over that period. The shares therefore remain within a tight trading band in the mid-$60s, suggesting that the market is still calibrating the impact of recent news rather than repricing the stock aggressively.

At the same time, the intraday high of $66.31 on August 4, 2026 provides a recent reference point for resistance. With the current price around $64.66, Bristol Myers Squibb stock is trading about $1.65 below that early-August peak, a gap that investors will watch as pipeline and regulatory updates accumulate through the remainder of 2026.

ZENBEXUS highlights product execution

ZENBEXUS, Bristol Myers Squibb’s newly approved iberdomide-based therapy, exemplifies the company’s focus on advancing treatments for hematologic malignancies. The ZDd combination regimen, pairing iberdomide with daratumumab and hyaluronidase-fihj plus dexamethasone, is specifically indicated for adult multiple myeloma patients who have already been treated with a proteasome inhibitor and an immunomodulatory agent, positioning it for use in settings where disease has progressed after standard therapies. The FDA approval announcement describes ZENBEXUS as an iberdomide-based regimen combined with daratumumab, hyaluronidase-fihj and dexamethasone for previously treated multiple myeloma patients.

The accelerated approval pathway requires Bristol Myers Squibb to provide confirmatory evidence in later-stage trials, but it also enables earlier commercial access for patients, creating an immediate opportunity to generate revenue while broader studies continue. Uptake of ZENBEXUS in the first few quarters post-approval will be a key indicator of the product’s commercial potential and will contribute to the company’s hematology segment performance.

ZENBEXUS joins Bristol Myers Squibb’s established multiple myeloma offerings and contributes to a diversified oncology portfolio that spans blood cancers and solid tumors. By reinforcing its presence in this indication with a fresh mechanism of action and combination strategy, Bristol Myers Squibb aims to sustain growth against competitive pressures and evolving treatment standards.

Shares and closing price context

As of the close on August 13, 2026, Bristol Myers Squibb stock trades at $64.66 on the New York Stock Exchange in U.S. dollars, according to a recent quote snapshot. The same data show a daily percentage change of 1.50 percent, indicating that the shares advanced modestly during that session. The NYSE-listed Bristol Myers Squibb shares are quoted at $64.66 with a 1.50 percent gain for the August 13, 2026 session.

For investors, this price level sits close to both recent highs and the average analyst target of $64.92, reinforcing the view that Bristol Myers Squibb stock currently reflects a balance between pipeline opportunities like ZENBEXUS and collaboration progress, and ongoing execution risks in a competitive biopharmaceutical landscape.